Polio: a VaccinesWork guide
Polio: a VaccinesWork guide
24 October 2024
A polio worker going for field work during door-to-door national polio campaign in UC Jalala in Texila, Pakistan. Gavi/Pakistan/Asad Zaidi
This week, Gavi's VaccinesWork shines its spotlight on polio, a disease the world is on the verge of vanquishing.
This week, VaccinesWork is shining its spotlight on polio, a disease the world is on the verge of vanquishing. Stay with us to learn about the people, and plans, fuelling that final furlong.
By Maya Prabhu and James Fulker
Announcements
IFFIm impact: polio
IFFIm has contributed a total of US$ 355 million to Gavi for polio programmes.
There are many good ways to measure the almost there of the global drive to eradicate poliomyelitis.
Cases of wild polio have dropped 99% since 1988, when the Global Polio Eradication Initiative (GPEI) was established. Two out of three strains of the wild-type virus have been eradicated. The remaining strain, termed wild poliovirus type 1 (WPV1), inhabits a drastically shrunken geography, endemic in just Afghanistan and Pakistan.
While in 1988 an estimated 350,000 people in 125 countries fell ill with the paralysing disease, last year, our two remaining endemic countries recorded just 12 cases of WPV1-linked disease between them. Conversely, 20 million more people are walking today who wouldn’t otherwise have been.
Vaccines – a tag-team of them – have played in integral role in getting us this close to the end, and they’ll get us the rest of the way to eradication too. But the final percent will take an uphill push.
That’s because the poliovirus forces a high standard for safety: according to the World Health Organization, the threshold for herd immunity is 80%.
And wild-type polio virus isn’t the only paralysing threat out there. Variant polio, which crops up in rare cases when the weakened, safe strain of the virus in the oral vaccine has too much opportunity to spread unchecked, mutating along the way – in other words, in places where vaccine coverage is low in the first place – is also capable of seeding outbreaks.
When polio begins to spread, it travels stealthily: just one in 200 cases is symptomatic. That makes the virus adept at exploiting even narrow cracks in a population’s immunity.
Those cracks tend to gape amid war and disaster, inviting misfortune to compound misfortune. It’s no coincidence that cases of polio have cropped up among the besieged children of Gaza, in bombarded Ukraine, in troubled northern Nigeria, and in Afghanistan.
Any outbreak, anywhere, is a fire that can throw a spark. In 2022, a toddler in Lilongwe fell ill with WPV1 – Malawi’s first case in decades. Genetic analysis of the virus proved it was related to a strain traceable to Sindh province, Pakistan, in 2019. Neither the child nor her family had travelled.
There’s really only one solution: the cracks need closing. That requires both expertise and financial resources. Gavi and its partners in GPEI know how to get the work done – but both Gavi and GPEI need funding to do it.
Stick with us this week to read more dispatches from the end-zone of eradication. Until then, here are some of our favourite polio stories from the archive.
- The VaccinesWork Editors
The endgame: What will it take to eradicate polio?
Polio cases are down from hundreds of thousands every year in the 1980s to just a few hundred today. We are close to making polio the second human disease to be eradicated, but what will it take to finally consign this killer disease to the history books?
Read story
Wild polio’s return to Africa: How the GPEI stopped an outbreak from becoming an inferno
In February 2022, a year and a half after the continent was declared free of indigenous poliovirus, a case surfaced in south-eastern Africa. The circumstances proved that it’s not over until it’s over everywhere.
Read story
Motorbike-riding polio worker ruffles feathers and saves lives in rural Pakistan
Amina Khaskheli discovered she can reach more kids on two wheels than on two feet – so that’s what she’s doing. If the sight of her on her bike has upset some conservative onlookers, it has also inspired more than a few young girls.
Read story
“Reaching the unreached” in one of the last strongholds of poliovirus
In Pakistan’s most polio-troubled region, a new strategy sees encouraging successes.
Read story
The iron lung
Before 1955, when a vaccine first made polio a preventable illness, the paralysing disease had to be treated. For many, the best option was the iron lung, a device that came to symbolise an era of anxiety in mid-20th century America.
Read story
 | This article is republished from VaccinesWork under a Creative Commons license. Read the original article. VaccinesWork is an award-winning digital platform hosted by Gavi, the Vaccine Alliance covering news, features and explainers from every corner of global health and immunisation. |
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.